Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart G Tangye

Showing results (281-290 of 284) with videos related to

Pageof 29
Sort By:
You have reached the last page of results.This site can display upto 284 results.
The Journal of Allergy and Clinical Immunology|October 13, 2022
Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndromeJennifer W Leiding, Tiphanie P Vogel, Valentine G J Santarlas, et al.
Nature|November 8, 2023
Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiencyTom Le Voyer, Audrey V Parent, Xian Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2022
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesJérémy Manry, Paul Bastard, Adrian Gervais, et al.
Science Immunology|August 20, 2021
Autoantibodies neutralizing type I IFNs are present in <b>~</b>4% of uninfected individuals over 70 years old and account for <b>~</b>20% of COVID-19 deathsPaul Bastard, Adrian Gervais, Tom Le Voyer, et al.
Pageof 29

Showing results (281-290 of 284) with videos related to

Sort By:
Pageof 29
You have reached the last page of results.This site can display upto 284 results.
The Journal of Allergy and Clinical Immunology|October 13, 2022
Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndromeJennifer W Leiding, Tiphanie P Vogel, Valentine G J Santarlas, et al.
Nature|November 8, 2023
Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiencyTom Le Voyer, Audrey V Parent, Xian Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2022
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesJérémy Manry, Paul Bastard, Adrian Gervais, et al.
Science Immunology|August 20, 2021
Autoantibodies neutralizing type I IFNs are present in <b>~</b>4% of uninfected individuals over 70 years old and account for <b>~</b>20% of COVID-19 deathsPaul Bastard, Adrian Gervais, Tom Le Voyer, et al.
Pageof 29